GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views
The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
GSK Expects Further Profit Growth After Beating Market Views
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
GSK lifts long-term sales targets on new drug pipeline
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
GSK falls Tuesday, underperforms market
GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.
Earnings dominate sentiment, as GSK shines, and Google dives
As we mentioned on Tuesday, the majority of companies on the S&P 500 that have reported earnings, have beaten estimates, and ...
GSK FY24 Core Operating Profit Rises, Turnover Up 7% At CER; Increases 2031 Sales Outlook
GSK (GSK.L, GSK) reported fiscal 2024 profit before tax of 3.5 billion pounds, down 43% at AER, or down 34% at CER from prior year.
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...
GSK Sales, Core Earnings Expected to Fall -- Earnings Preview
CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...
Glaxo: Q4 Earnings Snapshot
On a per-share basis, the Brentford, Britain-based company said it had net income of 26 cents. Earnings, adjusted for non-recurring costs, were 59 cents per share. The results topped Wall Street ...